Insider Transactions in Q2 2024 at Biogen Inc. (BIIB)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 21
2024
|
Jesus B Mantas Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,340
+15.35%
|
-
|
|
Jun 21
2024
|
Stephen A Sherwin Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,340
+6.26%
|
-
|
|
Jun 21
2024
|
Monish D Patolawala Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,340
+50.0%
|
-
|
|
Jun 21
2024
|
Susan Langer Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,340
+32.69%
|
-
|
|
Jun 21
2024
|
Eric K Rowinsky Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,340
+5.75%
|
-
|
|
Jun 21
2024
|
Maria C Freire Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,340
+23.16%
|
-
|
|
Jun 21
2024
|
William A Hawkins Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,340
+17.11%
|
-
|
|
Jun 21
2024
|
Caroline Dorsa Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,785
+6.29%
|
-
|
|
May 01
2024
|
Adam Keeney Head of Corporate Development |
SELL
Payment of exercise price or tax liability
|
Direct |
276
-29.42%
|
$59,616
$216.13 P/Share
|
|
May 01
2024
|
Adam Keeney Head of Corporate Development |
BUY
Exercise of conversion of derivative security
|
Direct |
938
+50.0%
|
-
|
|
Apr 02
2024
|
Priya Singhal Head of Development |
SELL
Open market or private sale
|
Direct |
93
-1.87%
|
$19,809
$213.09 P/Share
|
|
Apr 01
2024
|
Nicole Murphy Head of Pharm Ops and Tech |
SELL
Payment of exercise price or tax liability
|
Direct |
117
-1.2%
|
$25,038
$214.83 P/Share
|
|
Apr 01
2024
|
Nicole Murphy Head of Pharm Ops and Tech |
BUY
Exercise of conversion of derivative security
|
Direct |
240
+2.4%
|
-
|